The phrase "rheumatoid arthritis" almost right away calls to mind Genentech Inc.'s Rituxan (rituximab, which targets the CD20 antigen, for RA and non-Hodgkin's lymphoma). (BioWorld Financial Watch)

Shares of Israel-based Protalix BioTherapeutics Inc. crashed on word that the company priced 10 million shares of its stock at only $5 per share, as Wall Street cut the firm's market cap - hefty after last summer's merger with the shell firm Orthodontix Inc. - severely down to size. (BioWorld Today)